PETAH TIKVA, Israel - NANO-X IMAGING LTD (Nasdaq: NNOX), a medical imaging technology company, in partnership with Beilinson Hospital, part of the Rabin Medical Center, has initiated a clinical study to evaluate the Nanox.ARC, a novel 3D imaging system.
The study aims to compare the diagnostic capabilities of the Nanox.ARC's tomographic imaging to conventional 2D radiography for lung and chest disease detection in adults.
The Nanox.ARC utilizes a digital tomosynthesis system that employs multiple X-ray sources to generate three-dimensional images. This technology could potentially streamline the diagnostic process by providing additional information, which may reduce the need for more advanced imaging and exposure to further radiation.
The current study at Beilinson Hospital, renowned for its advancements in radiology, is led by Professor Eli Atar, M.D., and Dr. Ahuva Grubstein, M.D. It represents an expansion of the ongoing collaboration between Nanox and Clalit Health Services, Israel's largest healthcare organization.
Nanox's CEO, Erez Meltzer, expressed optimism about the study's potential to validate the Nanox.ARC as part of a comprehensive medical imaging solution. Professor Atar also conveyed positive expectations for the technology, emphasizing its promise in enhancing clinical precision and facilitating early disease detection.
This collaboration follows a previous study at Beilinson Hospital that used Nanox AI's HealthCCSng solution on chest CT scans, revealing undetected cardiovascular risks in approximately 40% of patients.
Nanox, listed on NASDAQ as NNOX, focuses on making diagnostic imaging more accessible and affordable worldwide. The company's ecosystem includes the Nanox.ARC, an AI-based suite of algorithms for routine CT imaging, a cloud-based infrastructure, and a proprietary marketplace offering remote access to radiology and cardiology experts.
The press release statement contains forward-looking projections regarding Nanox's technology and commercialization efforts. These statements are subject to various risks and uncertainties, including the development and regulatory approval of the Nanox System and the realization of expected benefits from recent acquisitions.
The information in this article is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.